

# Forum diabetologicum 2013; 2

## Regisler klúčových slov

kľúčové slovo	(číslo): strany	kľúčové slovo	(číslo): strany
akútne srdcové zlyhávanie	(1): 23–26	gliptíny	(2): 130–139
akútny koronárny syndróm	(1): 23–26	gravidita	(3): 176–180
aliskirén	(1): 11–17	hypertriacylglycerolémie	(3): 181–184
antiagregáční lečba	(2): 68–73	hypolipidemika	(2): 140–145
antidiabetiká	(1): 18–22	chronická rana	(2): 68–73
antihypertenzívne lieky	(1): 11–17	indikačné obmedzenia	(2): 98–101
anti-VEGF	(3): 185–188	inhibitory ACE	(2): 130–139
AT1-blokátory	(2): 68–73	intenzifikovaný inzulínový režim	(2): 122–124
aterogénná dyslipidémia	(2): 140–145	inzulín lispro mix	(2): 122–124
ateroskleróza	(2): 140–145	jednoduchosť a finančná nenáročnosť	(2): 98–101
autonómna neuropatia	(2): 108–116	kardioreálny syndróm	(1): 31–35
bazálne analógy inzulínu	(2): 130–139	kardiovaskulárne ochorenia	(1): 27–30
cievy	(2): 90–97	kardiovaskulárni mortalita	(2): 102–107
cílová hodnota krevního tlaku	(2): 68–73	kardiovaskulárni riziko	(3): 165–168
časná inzulinová terapie diabetu 2. typu	(3): 165–168	komorová fibrilácia	(1): 36–40
časná kombináční lečba	(3): 165–168	kompliancia	(1): 11–17
časná léčba diabetu	(3): 165–168	komplikácie	(2): 108–116
dermoepidermálne štopy	(2): 98–101	larvoterapia	(2): 74–83
diabetes mellitus	(1): 18–22	laserová liečba	(3): 176–180
	(1): 23–26	léčba prediabetu	(3): 165–168
	(1): 27–30	liečba pomocou živých bunkových linií	(2): 74–83
	(1): 31–35	liečba riadeným podtlakom	(2): 74–83
	(1): 36–40	mikroalbuminúria	(2): 117–121
	(2): 102–107	mikroalbuminurie	(2): 68–73
	(2): 108–116	multiorgánovomultivaskulárna choroba	(1): 36–40
	(2): 117–121	nefroprotekce	(2): 68–73
	(3): 190–192	nevaskularizácie terča zrakového nervu	(3): 185–188
diabetes mellitus 1. typu	(3): 185–188	nevaskulárny glaukóm	(3): 190–192
diabetes mellitus 2. typu	(2): 122–124	pars plana vitrektómia	(3): 170–175
diabetes mellitus-výskyt	(3): 193–199	periférna neuropatia	(2): 108–116
diabetická kardiomyopatia	(1): 18–22	podiatrické centrum	(2): 102–107
diabetická nefropatia	(1): 31–35	prediabetes	(3): 165–168
	(2): 117–121	predsieňová fibrilácia	(1): 27–30
	(S1): 1–6	premixované inzulínové analógy	(2): 122–124
diabetická noha	(2): 74–83	prevence diabetu	(3): 165–168
	(2): 90–97	primárny glaukóm s otvoreným uhlom	(3): 190–192
	(2): 98–101	ranibizumab	(3): 185–188
diabetická retinopatia	(3): 170–175	rehospitalizácie pre akútne ochorenia	(1): 23–26
	(3): 176–180	rizikové faktory	(2): 84–89
	(3): 181–184	skrining	(3): 176–180
	(3): 193–199	srdcové zlyhávanie	(1): 18–22
diabetické ulcerace	(2): 102–107	syndróm diabetickej nohy	(2): 84–89
diabetický edém makuly	(3): 170–175	tehotenstvo	(3): 181–184
	(3): 185–188	tlak vnutroočný	(3): 190–192
	(3): 193–199	tolerancia	(1): 11–17
diagnostika diabetickej nefropatie	(2): 117–121	transplantácia autológnych štěpov	(2): 98–101
dyslipoproteinémia	(2): 140–145	trvanie účinku	(1): 11–17
endovaskulárne výkony	(2): 90–97	zobrazovacie metódy	(2): 90–97
etiopatogenéza	(2): 84–89		
glaukóm	(3): 190–192		

# Forum diabetologicum 2013; 2

## Index of key words

key word	(číslo): strany	key word	(číslo): strany
ACE inhibitors	(2): 68–73		(3): 176–180
acute coronary syndrome	(1): 23–26		(3): 181–184
acute heart failure	(1): 23–26		(3): 193–199
aliskiren	(1): 11–17	diagnosis of diabetic nephropathy	(2): 117–121
angiotensin receptor blockers	(2): 68–73	duration of action	(1): 11–17
antidiabetics	(1): 18–22	dyslipoproteinemia	(2): 140–145
antihypertensive drugs	(1): 11–17	early combination treatment	(3): 165–168
antiplatelet therapy	(2): 68–73	early insulin treatment in type 2 diabetes	(3): 165–168
anti-VEGF	(3): 185–188	early treatment of diabetes	(3): 165–168
atherogenic dyslipidemia	(2): 140–145	endovascular intervention	(2): 90–97
atherosclerosis	(2): 140–145	etiopathogenesis	(2): 84–89
atrial fibrillation	(1): 27–30	forgiveness	(1): 11–17
autonomic neuropathy	(2): 108–116	glaucoma	(3): 190–192
basal insulin analogues	(2): 130–139	gliptines	(2): 130–139
blood vessels	(2): 90–97	goal blood pressure	(2): 68–73
cardiorenal syndrome	(1): 31–35	heart failure	(1): 18–22
cardiovascular disease	(1): 27–30	hypertriglyceridemia	(2): 140–145
cardiovascular mortality	(2): 102–107	chronical wound	(2): 98–101
cardiovascular risk	(3): 165–168	imaging methods	(2): 90–97
compliance	(1): 11–17	indicating restrictions	(2): 130–139
complications	(2): 108–116	insulin lispro mix	(2): 122–124
dermoepidermal skin grafts	(2): 98–101	intensified insulin regimen	(2): 122–124
diabetes mellitus	(1): 18–22	intraocular pressure	(3): 190–192
	(1): 23–26	laser treatment	(3): 176–180
	(1): 27–30	lipid-lowering drugs	(2): 68–73
	(1): 31–35	maggot therapy	(2): 74–83
	(1): 36–40	microalbuminuria	(2): 68–73
	(2): 102–107	multiorganomultivascular arterial disease	(2): 117–121
	(2): 108–116	neovascular glaucoma	(1): 36–40
	(2): 117–121	nephroprotection	(3): 190–192
	(3): 190–192	optic disc neovascularization	(2): 68–73
diabetes mellitus type 1	(3): 185–188	pars plana vitrektómia	(3): 185–188
diabetes mellitus type 2	(2): 122–124	peripheral neuropathy	(3): 170–175
diabetes mellitus-incidence	(3): 193–199	prediabetes	(2): 108–116
diabetes prevention	(3): 165–168	prediabetes treatment	(3): 165–168
diabetic cardiomyopathy	(1): 18–22	pregnancy	(3): 165–168
diabetic foot	(2): 74–83	premixed insulin analogues	(3): 176–180
	(2): 90–97	primary open-angle glaucoma POAG	(3): 181–184
	(2): 98–101	ranibizumab	(2): 122–124
diabetic foot clinic	(2): 102–107	rehospitalization for acute diseases	(3): 190–192
diabetic foot syndrome	(2): 84–89	risk factors	(3): 185–188
diabetic foot ulcer	(2): 102–107	screening	(1): 23–26
diabetic macular edema	(3): 170–175	simplicity and low cost	(2): 84–89
	(3): 185–188	transplantation of autolog skin grafts	(3): 176–180
	(3): 193–199	treatment with controlled vacuum	(2): 98–101
diabetic nephropathy	(1): 31–35	treatment with live cell lines	(2): 74–83
	(2): 117–121	ventricular fibrillation	(2): 74–83
	(S1): 1–6		(1): 36–40
diabetic retinopathy	(3): 170–175		